Literature DB >> 12812388

Glanzmann's thrombasthenia proposed optimal management during surgery and delivery.

Julie-Anne Bell1, Geoffrey F Savidge.   

Abstract

Glanzmann's thrombasthenia (GT) is an autosomal recessive disorder of platelet function. Conventional management is by platelet transfusion, given before invasive interventions. Alloimmunization resulting in platelet refractoriness and an unpredictable response to platelet infusion have provided particular management difficulties in the past. More recently recombinant (r)VIIa (Novoseven) has a valuable role in the treatment of platelet function disorders. Treatment of a patient with GT during two pregnancies and spinal surgery is reported. An algorithm is presented to provide a structured and consistent approach to treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12812388     DOI: 10.1177/107602960300900213

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  3 in total

1.  Glanzmann's Thrombasthenia Diagnosed following Knee Arthroscopy.

Authors:  John E Zvijac; Sharhabil S Ammus; Fernando Aran; Gary M Kiebzak
Journal:  Case Rep Orthop       Date:  2015-04-27

2.  Menstrual and obstetrical bleeding in women with inherited platelet receptor defects-A systematic review.

Authors:  Marieke C Punt; Pauline C E Schuitema; Kitty W M Bloemenkamp; Idske C L Kremer Hovinga; Karin P M van Galen
Journal:  Haemophilia       Date:  2020-01-31       Impact factor: 4.287

Review 3.  Clinical use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann's thrombasthenia.

Authors:  Man-Chiu Poon
Journal:  Vasc Health Risk Manag       Date:  2007
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.